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Previous studies have shown that the sickle environment is highly enriched for reactive oxygen species (ROS). We examined the
oxidative eﬀects of sickle cell disease on hematopoietic stem cell function in a sickle mouse model. In vitro colony-forming assays
showed a signiﬁcant decrease in progenitor colony formation derived from sickle compared to control bone marrow (BM). Sickle
BM possessed a signiﬁcant decrease in the KSL (c-kit+,S c a - 1+, Lineage−) progenitor population, and cell cycle analysis showed
that there were fewer KSL cells in the G0 phase of the cell cycle compared to controls. We found a signiﬁcant increase in both lipid
peroxidation and ROS in sickle-derived KSL cells. In vivo analysis demonstrated that normal bone marrow cells engraft with
increased frequency into sickle mice compared to control mice. Hematopoietic progenitor cells derived from sickle mice, however,
demonstrated signiﬁcant impairment in engraftment potential. We observed partial restoration of engraftment by n-acetyl
cysteine (NAC) treatment of KSL cells prior to transplantation. Increased intracellular ROS and lipid peroxidation combined with
improvement in engraftment following NAC treatment suggests that an altered redox environment in sickle mice aﬀects hemato-
poietic progenitor and stem cell function.
1.Introduction
Sickle cell disease (SCD) is one of the most common inher-
ited hemoglobinopathies in the world. In the United States,
approximately 1 in 600 African Americans have been diag-
nosed with SCD [1] .S C Di sa na u t o s o m a lr e c e s s i v eg e n e t i c
disorder caused by a substitution of glutamic acid by valine
inthebetasubunitofthehemoglobingene.Thissubstitution
results in the production of abnormal hemoglobin (HbS).
Deoxygenated HbS polymerizes, resulting in intravascular
hemolysisoftheredbloodcellandreleaseofhemoglobinand
other compounds into the plasma [2]. Repeating cycles of
polymerization and hemolysis lead to vaso-occlusion and
ischemia-reperfusion injury. Inherent in these processes are
inﬂammatory responses and oxidant stress which result in
pathological outcomes such as acute chest syndrome, pul-
monary hypertension, and stroke in patients with SCD [3].
Oxidative stress is a result of increased production of
reactive oxygen species (ROS) combined with decreased pro-
duction or availability of antioxidants. Cellular metabolism
of oxygen can lead to the production of ROS such as super-
oxide anion radicals, hydrogen peroxide, and hydroxyl
radicals. ROS can impair the proper function of DNA, lipids,
proteins,andcarbohydrates[4].Animbalanceintheamount
of pro-oxidants and antioxidants leads to an environment of
oxidative stress, cell dysfunction, or cell death. Antioxidants2 Anemia
such as nitric oxide (NO), superoxide dismutase (SOD),
and reduced glutathione (GSH) function to neutralize excess
ROS.
ThereisincreasingevidencethatoxidativestressandROS
play a pivotal role in the pathophysiology of numerous dis-
eases including neurodegenerative diseases, cardiovascular
diseases, cancers, and arthritis [5–10]. Oxidative stress has
been linked to vascular defects leading to hypertension and
atherosclerosisaswellascardiacdefectsleadingtocontractile
dysfunction and dysrhythmias [11]. In addition to the ability
to induce mutations in DNA, ROS play a key role in cell
signaling and cell regulatory pathways and thus play a pivotal
roleinthedevelopmentoftumorsandmalignancies[12–16].
In SCD, under low-oxygen conditions, HbS polymerizes
leading to hemolysis and a signiﬁcantly shortened lifespan
[17]. Hemolysed RBCs release hemoglobin, iron, and argin-
ase into the plasma resulting in decreased nitric oxide avail-
ability and leading to imbalanced vascular homeostasis and
oxidative stress [17–19]. Sickle RBCs generate more super-
oxide, hydrogen peroxide, and lipid oxidation products
compared to normal RBCs [20]. Increased ROS in platelets
and polymorphonuclear neutrophils along with decreased
glutathione levels has also been documented in patients with
SCD [21]. In addition, endothelium exposed to sickled RBCs
become activated, causing sickled RBCs and leukocytes to
adhere to the activated endothelium, resulting in a release of
cytokines and ROS [6, 22, 23]. In this study, we studied the
eﬀects of this pro-oxidant and proinﬂammatory environ-
ment on hematopoietic progenitor and stem cells in the
Berkeley model of sickle cell disease.
2.MaterialsandMethods
2.1. Animals. Sickle mice, originally supplied by Dr. P´ aszty
[24], express exclusively human α-, βsickle,a n dγ-globin and
exist on a mixed genetic background (FVB/N, 129, DBA/2,
C57BL/6, and Black Swiss). Breeding and pregnant sickle
mice were fed TestDiet no. 0007573 (Purina). The colony is
maintained by breeding female hemizygous mice with 2
copies of the transgene to homozygous male mice. The
resulting pups are hemizygous, expressing one (H-1) or two
(H-2) copies of the transgene, one copy of murine beta
globin, but no expression of murine alpha globin. Homozy-
gous “sickle” mice that only express human gamma, alpha,
andbetasickle globinsareeasilydistinguishablefromwildtype
and the H-1 and H-2 hemizygotes by hemoglobin electro-
phoresis (Figure 1)[ 24, 25]. H-1 mice have ∼28% sickle
hemoglobin and H-2 mice have ∼45%. Despite having only
one copy of the sickle hemoglobin transgene, H-1 mice are
hematologically more severe (Figure 1). H-2 and C57BL/6
were primarily used as control mice for the homozygous
mice. All breeding and experimental procedures were per-
formed at Emory University in accordance with the rec-
ommendations of the Institutional Animal Care and Use
Committee (IACUC).
2.2. Flow Cytometry. Bone marrow was harvested and stained
with the following ﬂuorochrome-conjugated antibodies:
CD45.1-PE, CD45.2-APC, c-kit-FITC, Sca1-PE, and Lin-
eage-APC (B220, CD3, CD11b, GR-1, and Ter119; BD
Pharmingen, San Diego, CA), and KSL cells were sorted on
a FACSAria. Cells from the peripheral blood were analyzed
at various time points on an LSR II ﬂow cytometer (BD
Biosciences, San Jose, CA). Propidium iodide was used to
exclude dead cells. For ROS analysis, cells were incubated in
160μM Dichlorodihydroﬂuorescein diacetate (H2DCFDA)
(St. Louis, MO, Sigma-Aldrich) or 5μM N-(ﬂuorescein-
5thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phos-
phoethanolamine, triethylammonium salt (DHPE) (Carls-
bad, CA, Invitrogen) in HBSS for 15min or 60min, res-
pectively, at 37◦C shaking in the dark. Cells were washed
a n da n a l y z e db yﬂ o wc y t o m e t r y .A b s o l u t ec e l lc o u n t sw e r e
performed using Trucount tubes (BD Biosciences).
2.3. HPP Assay. Twenty thousand freshly isolated bone
marrow mononuclear cells were plated in methylcellulose
medium (StemCell Technologies Inc., Vancouver) contain-
ing recombinant cytokines (100ng rat steel factor, 1600U
m-CSF, 75U IL-3, 5000U IL-1α,3 0 n g / m LE G F ,a n d
30ng/mL FGF) to analyze the colony-forming potential of
stem cells derived from the bone marrow of sickle and
control mice. Cells were cultured for 10 days, and colonies
were counted using an inverted microscope.
2.4. Hemoglobin Analysis. Diﬀerential hemoglobin electro-
phoresis of peripheral blood from Berkeley sickle mice was
performed to determine hetero- and homozygosity of the
murine and human globin genes (Helena Titan III electro-
phoresis system, Helena Laboratories, Beaumont, TX) [26].
As shown in Figure 1, C57BL/6 mice express the murine beta
globin “single” allele, the H-1 and H-2 hemizygotes express
increasingamountsofhumanbetasickle globininthepresence
of the murine allele expressing “diﬀuse” beta globin, and the
mice homozygous for the deletions of murine alpha and beta
globins express only human betasickle globin.
2.5. Transplants
2.5.1. The Eﬀect of the Recipient Environment. To test the
eﬀects of transplanting into the sickle microenvironment,
1 × 107 bone marrow cells from C57BL/6 mice (expressing
CD45.2) were transplanted into homozygous sickle (n = 8)
and B6.SJL-Ptprca Pepcb/BoyJ mice (n = 10; both expressing
CD45.1) without ablation. While sickle and C57BL/6 share
the MCH class I allele H-2Kb, their genetic backgrounds are
not identical and therefore are unlikely to share the full hap-
lotype. We have previously shown that T-cell costimulation
blockade promotes engraftment across allo-barriers in this
model, and it was therefore included in this protocol. Specif-
ically, 500μg each of hamster antimouse-CD40L (MR1;
BioExpress, Lebanon, NH) and human CTLA4-immuno-
globulin (generous gift from Dr. C. Larsen) was given intra-
peritoneally on days 0, 2, 4, and 7 relative to BMT.
2.5.2. Competitive Repopulation Study. To test the repop-
ulation capacity of individual stem cell populations, threeAnemia 3
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Figure 1: Hemoglobin and hematology proﬁle of Berkeley sickle mice. Hemoglobin electrophoresis of RBC from C57BL/6, H-2, H-1, and
homozygous sickle mice. C57BL/6 mice show a “single” hemoglobin band, whereas the H-2 and H-1 hemizygotes show beta-sickle globin
resultingfromtwooronecopyofthetransgene,respectively,incombinationwiththeminorbandofdiﬀusebeta-globins.Homozygoussickle
mice only have the characteristic band of beta-sickle globin. The complete blood counts of C57BL/6 mice, H-2, H-1, and homozygous sickle
mice (n = 10 per genotype) are also shown with the hemizygous mice having intermediate values between C57BL/6 mice and homozygous
sickle mice.
thousand KSL cells derived from homozygous H-2 sickle,
or B6.SJL-Ptprca Pepcb/BoyJ, were sorted using a FACSAria
(BDBiosciences,SanJose,CA)andwerecotransplantedwith
2×106 c ompetiti v ebonemarr o wc ellsderi v edfr omC57BL/6
mice. Due to the potential diﬀerences in background, F1
recipient mice were generated by breeding H-2 sickle mice
(expressing CD45.1) to C57BL/6 mice (expressing GFP
under the beta globin promoter and CD45.2). These recip-
ient mice expressed GFP+, CD45.1, and CD45.2 double pos-
itive cells (F1 mice). All recipients (n = 4e a c hg r o u p )w e r e
conditioned with two doses of 550 cGy total body irradiation
on the day of BMT. To test the ability of the glutathione
precursor to alleviate oxidant stress in the selected stem cell
populations, groups of donor mice were also treated for four
weeks with 0.163g/L n-acetyl cysteine (NAC) in their drink-
ing water (fresh NAC drinking water was made every two
days). Mice were 12 weeks of age at the time of bone marrow
harvest and transplantation.
3. Statistics
All statistical comparisons were performed using GraphPad
Prism software utilizing one-way ANOVA with a Tukey
posttest analysis unless otherwise stated (∗P<0.05; ∗∗P<
0.01; ∗∗∗P<0.001).4 Anemia
4. Results
4.1. Stem Cell Number and Function. Absolute cell counts
were performed for stem/progenitor cells that were negative
for markers of mature hematopoietic cells (T-cells, CD3; B-
cells, B220; RBC, Ter-119; Myeloid cells, GR-1/Mac-1) while
being positive for c-kit and Sca-1 (KSL, Figure 2(a)). Sickle
mice had signiﬁcantly fewer stem cells than control mice. We
further quantiﬁed the number of a deﬁned hematopoietic
stem cell population (HSC; KSL/CD150+/CD48−)[ 27].
These cells were also signiﬁcantly reduced in homozygous
mice compared to controls (t-test, Figure 2(b)). As there
were less stem cells in the bone marrow, we investigated the
cell cycle status of HSC as a reduction in the number of
quiescent cells (G0 of the cell cycle) has been associated with
mobilization of HSC in normal tissues, and HSCs are
reported to be mobilized in sickle cell patients [28].
Figure 2(c)showsareducednumberofcyclingKSLcellssug-
gesting a reduced number of quiescent stem cells in the bone
marrow. We then tested the functional capacity of KSL cells
using the in vitro high proliferative potential (HPP) assay.
Sickle-derived stem cells formed signiﬁcantly fewer colonies
compared to control (P<0.001, Figure 2(d)).
4.2. Oxidant Damage to Bone Marrow-Derived Cells. Using
ﬂow cytometric analysis and DCF and DHPE dyes, we mea-
suredtheintracellularcontentofROSandlipidperoxidation,
respectively, in KSL cells. H2DCFDA becomes deacetylated
by intracellular esterases as it crosses the membrane and
becomes brightly ﬂuorescent once oxidized by ROS produc-
ing DCF [29]. DHPE loses its ﬂuorescence upon reaction
with peroxy radicals [29]. Sickle-derived KSL cells demon-
strated signiﬁcantly increased lipid peroxidation and ROS
compared to those derived from normal and hemizygous
mice (P<0.05, Figures 2(e)–2(f)). Importantly, in all of the
above assays, the hemizygous mice showed an intermediate
phenotype that correlated to their hematological defect.
4.3. Engraftment in the Sickle Microenvironment. We then
addressed the issue of whether the sickle bone marrow envi-
ronment was more conducive to engraftment by donor cells.
To compare the engraftment eﬃciency of bone marrow cells
into control (C57BL/6) and homozygous sickle mice (sickle),
we transplanted 1 × 107 control male bone marrow cells into
mice receiving only costimulation blockade. As early as four
weeks after transplantation, there was a signiﬁcant increase
in engrafted donor cells in the sickle mice compared to the
control mice (P>0.001, Figure 3(a)). This level of engraft-
ment is remarkable considering the nonablative protocol,
and the continued increase with time suggests that donor
cells have a survival or proliferation advantage in the sickle
environment. Peripheral RBC markers also showed correc-
tion of sickle hematology towards control levels indicating
the survival advantage of normal over sickle RBC (Figures
3(b)–3(d))[ 30].
4.4. Engraftment Capacity of Sickle Hematopoietic Cells. We
then compared the engraftment potential of KSL cells
derived from control, hemizygous, and homozygous sickle
mice in a competitive repopulation assay to determine if
sickle-derived KSL cells were functionally impaired. First,
we bred male hemizygous sickle mice to female C57BL/6
mice to generate mice that expressed both CD45.1+ and
CD45.2+ antigens on the surface of their cells (F1) allowing
us to distinguish donor and host KSL as well as donor BM
competitor cells. By HPLC, we conﬁrmed that host F1 mice
carried one copy of the human β sickle globin gene, as
well as murine α and β globins (data not shown). For each
experiment, KSL cells were derived from untreated, as well as
NAC treated, control, hemizygous (H-2), and homozygous
mice and transplanted into lethally irradiated F1 mice.
Peripheral blood was analyzed at 4, 8, 12, 16, and 24 weeks
after transplantation (Figure 4(a)). In two separate experi-
ments, homozygous sickle-derived KSL cells demonstrated
signiﬁcantly reduced engraftment capabilities compared to
control mice. NAC treatment improved engraftment of
homozygous sickle KSL cells but did not fully correct the
defect (Figure 4(b)).
5. Discussion
Despite the beneﬁts of hydroxyurea, people with SCD have
limited treatment options with the only curative treat-
ment remaining hematopoietic stem cell transplant (HSCT).
Whilethenumbersofchildrenreceivingtransplanthavecon-
tinued to grow and now total in the hundreds, the majority
arestillperformedwithmyeloablativeconditioning (recently
reviewed in [31]). The outcomes of these transplants in
children are generally good with high levels of disease-free
survival.However[32],therearesigniﬁcantconcernsregard-
ing long-term toxicities and complications from the pre-
parative regimen, especially with regard to continued CNS
complications and gonadal toxicities [33].
The continued desire to be able to oﬀer transplant to a
muchlargerselectionofpatients,includingadults,hasdriven
a number of trials utilizing a variety of nonmyeloablative
protocols [34–36]. Most recipients have not had sustained
engraftment, but Hsieh et al. successfully transplanted a
small group of adults with mobilized peripheral blood from
matched sibling donors [37]. These limited successes, con-
tinued issues with posttransplantation immunosuppression,
and the limited number of HLA-matched donors will drive
alternative transplant protocols and techniques for therapy
with genetically corrected autologous cells.
These are similar ﬁndings to those in the murine model
of Ataxia telangiectasia (ATM), which also demonstrated sig-
niﬁcantimpairmentofstemcellpopulations atleastpartially
duetoROSandoxidativestress[38,39].Ataxiatelangiectasia
is a rare, recessive genetic disorder that causes neurological
degeneration. The Atm gene controls DNA repair, cell cycle,
and redox homeostasis. Ito et al. found that bone marrow-
derived stem cells from Atm knock-out mice possess
increased ROS and activated p38 MAPK that resulted in a
reduction in KSL number, decreased colony-forming poten-
tial, loss of quiescence, and defective self-renewal capacity
[38]. Similarly, sickle bone marrow has reduced colony-
formingpotential,andfewersickleHSCsareinG0 suggestingAnemia 5
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Figure 2: Stem cell number and oxidant state in Berkeley sickle mice. (a) Quantiﬁcation of KSL progenitor cells in the bone marrow
of control, hemizygous, and homozygous sickle mice showing a signiﬁcant reduction in number in homozygous sickle mice. (b) Further
examination of a phenotypically deﬁned HSC population (KSL/CD150+/CD48−) also shows a reduction of HSC in sickle BM. (c) HSCs in
the stem cell niche are known to be quiescent, and homozygous mice again show signiﬁcant reduction in KSL cells in the G0 phase of the
cell cycle possibly indicating the mobilization of sickle progenitor cells. (d) The in vitro colony-forming, high proliferative potential assay
(HPP) of stem/progenitor cells further indicates a signiﬁcant reduction in colony-forming cells in homozygous mice. (e) To examine the
eﬀect of oxidant stress on hematopoietic progenitors, we measured lipid peroxidation using the ﬂuorescent indicator DHPE. A reduction in
ﬂuorescence indicates increased activity of hydroxyl radicals. (f) Further quantiﬁcation of reactive oxygen species was shown in sickle mice
by the increased production of DCF (all graphs are presented as mean ± SD, ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001).6 Anemia
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Figure 3: Preferential engraftment in sickle mice. (a) Peripheral WBC populations from normal mice engraft in homozygous sickle mice at
a signiﬁcantly (P<0.01) faster rate than control mice when transplanted without ablation but in the presence of costimulation blockade.
The levels of WBC engraftment coincide with (b)–(d) corresponding correction of RBC, hemoglobin, and hematocrit in recipient mice.
that stem cells are mobilized. This is consistent with the
high peripheral WBC count in both mice and humans and
previous reports of mobilization in SCD.
The oxidant damage of murine sickle HSC further trans-
lates into a functional defect in a reduced activity in a com-
petitive repopulation assay. Interestingly, both hemizygote
and homozygotes were aﬀected. Antioxidant therapy in the
form of NAC provided partial correction of the phenotype.
Similar results were found in the ATM model where six
weeks of treatment with either NAC or catalase antioxidants
restored Atm−/− HSC CFU ability to near normal levels
[38]. In vivo full HSC engraftment was only achieved when
recipient mice were also treated with NAC. Oxidant-med-
iated HSC dysfunction is commonly seen in number of other
model systems including Fanconi anemia (Fancc−/−)w h e r e
ROSleadtoincreased apoptosis ofFancc−/− cells [40].AlackAnemia 7
S
S
C
FSC
(a)
L
i
v
e
/
d
e
a
d
Lineage
(b)
C
-
K
i
t
Sca-1
(c)
C
D
4
5
.
1
CD45.2
Con. 15%
F1 6%
Comp. 79%
M
(d)
C
D
4
5
.
1
CD45.2
F1 6%
Comp. 91%
Sickle 3%
M
(e)
C
D
4
5
.
1
CD45.2
F1 6%
Comp. 85%
Sickle + NAC 9%
M
(f)
0
10
20
30
40
50
60
70
Control
NAC
D
o
n
o
r
 
W
B
C
 
(
%
)
Control H-2 Sickle
∗
∗
∗∗
(g)
Figure 4: Functional defect of sickle hematopoietic stem cells in a competitive repopulation assay. Strategy for sorting KSL cells from whole
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Composite data showing a reduced capacity for engraftment between hemizygous and control mice and a further defect in KSL cells from
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partially restored engraftment of KSL cells from homozygous sickle cell mice.
ofFoxOfamilymembersalsoleadstoanincreaseinROSand
a reduction in both HSC number and reconstitution ability
[41]. In both of these models, antioxidant therapy with NAC
is able to reverse or ameliorate the defects. Oxidant mediated
stem cell damage is not limited to hematopoietic cells, for
example, Kim and Wong demonstrated an oxidant-mediated
defectinatm−/− neuralstemcellsthatwasresponsivetoNAC
[42]. It is interesting to speculate that the high levels of oxi-
dantstresscouldaﬀectotherorgan-speciﬁcstemcellpopula-
tions,andthatthismightbeanimportantfactorintheongo-
ing repair of sickle-related organ pathology. The HSC defects
should also be considered when designing gene therapy8 Anemia
protocols ﬁrst, as there may be a reduced number of HSCs
available for collection and secondly as the HSCs have a
reduced engraftment potential prior to ex-vivo manipula-
tion.
Clinically, patients with severe sickle disease, who would
be a desirable target population for HSCT, are likely to
encounter more complications during transplant due to
ongoing disease-related pathology and inﬂammation. How-
ever, with successful immunomodulatory strategies our data
would suggest that engraftment of HSC into the sickle
environment itself should be successful, and donor cells may
have a comparative advantage. This could be especially
important if designing approaches based on mixed hemato-
poieticchimerismthathavebeensuccessfullyusedinmurine
model systems [30, 43].
All of the major pathologic consequences of SCD such
RBC lysis, endothelial activation, and vaso-occlusion either
i n d u c eo re x ac e rb a t et h ep r od u cti o no fR O Swi t hs u b s eq u e n t
eﬀects being likely to contribute to further pathologic pro-
cesses (recently reviewed in [3, 4]). Consequently, a number
of investigators have studied the use of antioxidants in SCD,
mostly focusing on RBC eﬀects. Vitamins C and E and NAC
have all been shown to reduce ROS and increase the levels of
glutathione in sickle RBC and PMN in vitro [21]. Treatment
of NAC reduced the formation of dense RBC and increased
the levels of intracellular glutathione in RBC of patients with
SCD; importantly this correlated with a reduction in the
number of vaso-occlusive crises during the treatment period
[44]. Similarly, treatment with NAC for 6 weeks reduced
phosphatidyl serine exposure on the membrane of sickle
RBC and the levels of cell-free hemoglobin [45] indicating
ac e l l u l a re ﬀect for an oral antioxidant.
In summary, we describe the eﬀects of sickle-mediated
oxidant stress on the bone marrow environment and hema-
topoietic stem and progenitors and detail defects in HSC
function that raise important concerns when designing
future stem cell therapies for sickle cell disease.
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